HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid Tumors

Summary

HS-20093 is a humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. The objectives of this study are to investigate the anti-tumor activity, safety, pharmacokinetics and immunogenicity of HS-20093 in Chinese advanced esophageal carcinoma and other solid tumor patients.

Timeline

Start

2024-02-06

Primary completion

2026-07-31

Completion

2026-12-31

Drugs

Indications